Get the Stockscreener App
1.06
0.93%
-0.01
Pmv Pharmaceuticals Inc stock is traded at $1.06, with a volume of 66,482.
It is down -0.93% in the last 24 hours and up +20.70% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
See More
Previous Close:
$1.07
Open:
$1.07
24h Volume:
66,482
Relative Volume:
0.30
Market Cap:
$61.82M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-1.06
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
-0.93%
1M Performance:
+20.70%
6M Performance:
-29.80%
1Y Performance:
-34.57%
1-Day Range:
$1.03
$1.0901
1-Week Range:
$1.03
$1.18
52-Week Range:
$0.81
$1.82
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.06 | 61.82M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
Millennium Management LLC Has $480,000 Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in indie Semiconductor, Inc. (NASDAQ:INDI) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 12,462 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World
Squarepoint Ops LLC Increases Stake in Westwater Resources, Inc. (NASDAQ:WWR) - Defense World
Squarepoint Ops LLC Acquires 29,722 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
G-III Apparel Group (NASDAQ:GIII) Price Target Lowered to $18.00 at Barclays - Defense World
Blue Bird Co. (NASDAQ:BLBD) Shares Sold by California State Teachers Retirement System - Defense World
pmv pharmaceuticals holds virtual annual meeting, elects directors By Investing.com - Investing.com South Africa
pmv pharmaceuticals holds virtual annual meeting, elects directors - Investing.com
PMV Pharmaceuticals Holds 2025 Annual Stockholder Meeting - TipRanks
Jane Street Group LLC Has $75,000 Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Two Sigma Investments LP Buys 23,931 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
GAMMA Investing LLC Has $11.48 Million Stake in News Co. (NASDAQ:NWS) - Defense World
Ameriprise Financial Inc. Sells 16,715 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Bank of America Corp DE Has $932,000 Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Citadel Advisors LLC Purchases New Position in Invesco S&P SmallCap Consumer Staples ETF (NASDAQ:PSCC) - Defense World
Water Technologies International (OTCMKTS:WTII) Shares Pass Above 200-Day Moving Average – Here’s What Happened - Defense World
First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) Stock Price Passes Above 200-Day Moving Average – Should You Sell? - Defense World
Halma (LON:HLMA) Share Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Saputo (TSE:SAP) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Persimmon (LON:PSN) Stock Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Solstice Gold (CVE:SGC) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Bowl America (NYSEAMERICAN:BWL.A) Shares Pass Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Northern Trust Corp Has $162,000 Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
PMV Pharmaceuticals to Participate at Upcoming Investor Conferen - GuruFocus
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare Advances - Nasdaq
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMV Pharma CEO Reveals Latest Oncology Innovation Strategy at Two Major Healthcare Conferences - Stock Titan
D. E. Shaw & Co. Inc. Sells 16,189 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe - The Globe and Mail
We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate - Yahoo Finance
Crude Prices Rise on Doubts About a US-Iran Nuclear Deal - The Globe and Mail
Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail
PMVP Advances PYNNACLE Trial with Steady Enrollment | PMVP Stock News - GuruFocus
PMV Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
PMVP Reports First Quarter Cash Position and Operational Spendin - GuruFocus
Randy A. Bowman Appointed Chairman of the Board at Westwood Holdings Group - The Manila Times
PMV Pharmaceuticals Reports Progress in Phase 2 PYNNACLE Trial and First Quarter 2025 Financial Results - Nasdaq
JPMorgan Chase & Co. Buys 23,559 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
In the Green: PMV Pharmaceuticals Inc (PMVP) Closes at 0.87, Up/Down -7.34 from Previous Day - DWinneX
I Update My Buy Recommendation for Reddit Stock - The Globe and Mail
PMV Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Nutshell gains IND clearance for p53 Y220C reactivator NTS-071 - BioWorld MedTech
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mack David Henry | President and CEO |
Jan 03 '25 |
Option Exercise |
0.53 |
17,709 |
9,386 |
551,919 |
| Jalota Deepika | Chief Development Officer |
Sep 11 '24 |
Sale |
1.50 |
7,218 |
10,853 |
118,283 |
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):